Rossella Lauria

c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases.

Chiara Carlomagno, Francesco Perrone, Ciro Gallo et al. · Journal of Clinical Oncology · 1996 · 409 citations

Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial

Sandro Pignata, Giovanni Scambia, Dionyssios Katsaros et al. · The Lancet Oncology · 2014 · 386 citations

Advanced Ovarian Cancer, Medicine, Metronomic Therapy +7

The prognostic value of lymphatic and blood vessel invasion in operable breast cancer

Rossella Lauria, Chiara Carlomagno, Michelino De Laurentiis et al. · Cancer · 1995 · 181 citations · Full text

Topotecan Compared With No Therapy After Response to Surgery and Carboplatin/Paclitaxel in Patients With Ovarian Cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) Randomized Study

Sabino De Placido, Giovanni Scambia, Giovanni Di Vagno et al. · Journal of Clinical Oncology · 2004 · 164 citations · Full text

Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial

Sandro Pignata, Domenica Lorusso, Florence Joly et al. · The Lancet Oncology · 2021 · 144 citations

Carboplatin-based Doublet, Medicine, Metronomic Therapy +7